Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ra Pharmaceuticals Inc.

Division of Anthera Pharmaceuticals Inc./Alkira Therapeutics Inc.
www.rapharma.com

Latest From Ra Pharmaceuticals Inc.

UCB Acquires Engage To Boost Epilepsy Franchise

The Belgian drugmaker is getting hold of a device that delivers an inhaled formulation of the anxiety drug alprazolam which can rapidly terminate an epileptic seizure 30 seconds after it has begun.

M & A Neurology

For COVID, Consensus On Value Of Platform Trials, But A Confusion Of Consortia

The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.

Coronavirus COVID-19 Clinical Trials

Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study

The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.

Clinical Trials Neurology

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.

Immune Disorders Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register